跳至主要内容
临床试验/NCT01600001
NCT01600001已完成2 期

A Randomized, Double-blind, Placebo-controlled, Phase II Study of KWA-0711 in Patients With Chronic Idiopathic Constipation (CIC)

Kissei Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2012年5月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
75
试验地点
1
主要终点
Improvement of signs and symptoms associated with constipation

研究概览

简要总结

The purpose of this study is to evaluate the efficacy and safety of KWA-0711 in Chronic Idiopathic Constipation (CIC) patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patients who experienced fewer than three SBMs per week for more than 6 months prior to the enrollment
  • The patients who experienced one or more of the following signs or symptoms during more than 25% of bowel movements for more than 6 months: straining, lumpy or hard stools, and a sensation of incomplete evacuation

排除标准

  • Patients who have secondary constipation caused by systemic disorder
  • Patients who have organic constipation
  • Patients who received intestinal resection

研究组 & 干预措施

Drug:KWA-0711 dose 1

Experimental

干预措施: KWA-0711 (Drug)

Drug:KWA-0711 dose 2

Experimental

干预措施: KWA-0711 (Drug)

Drug:KWA-0711 dose 3

Experimental

干预措施: KWA-0711 (Drug)

Drug:KWA-0711 dose 4

Experimental

干预措施: KWA-0711 (Drug)

Drug: Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Improvement of signs and symptoms associated with constipation

时间窗: 4 weeks

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验